Latest Commercialization News

IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.

EV Resources has identified four new hydrothermal feeder veins and four breccia targets at its Los Lirios project, significantly expanding the drill-ready inventory ahead of a maiden JORC resource estimate.

Viridis Mining and Minerals completes a Definitive Feasibility Study for its Colossus Rare Earth Project, confirming strong economics and project readiness, while securing $120 million in equity funding to advance into execution.

Botala Energy reports promising early gas observations at its Serowe-3.5B well in Botswana, signaling reservoir responsiveness as the well approaches a critical dewatering stage in its Pitse Pilot.

AnteoTech has formalised a strategic alliance with South Korea’s Xerabrid to co-develop and commercialise a breakthrough battery separator combining their proprietary technologies, targeting high-performance applications in eVTOL, EVs, and consumer electronics.

Sparc Technologies launches a $2.5 million capital raise via a Share Purchase Plan and placement to fast-track commercial rollout of its graphene additive ecosparc® and support green hydrogen scale-up.

Western Gold Resources has lifted the Gold Duke Project’s Mineral Resource to 277,000 ounces of gold, marking a 29% increase in contained gold and a significant jump in resource confidence following extensive drilling.

Zinc of Ireland (ASX: ZMI) has fast-tracked its ARGO technology development to recover germanium, gallium, and indium, targeting early 2027 for pilot plant operations. The move aligns with EU regulatory demands for critical minerals and aims to reduce waste and emissions in zinc smelting.

Finder Energy’s KTJ offshore development in Timor-Leste has achieved a key milestone with an independent classification of 22.2 million barrels of 2P reserves, underpinning its push toward a Final Investment Decision.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Emyria has cleared a key operational hurdle by resolving Authorised Prescriber capacity constraints in Perth and Queensland, enabling a planned expansion of treatment days in Q4 2026 through the recruitment of 15 new therapists.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.